Clinical Trial Update: Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Ongoing Phase 1 study evaluating pembrolizumab (MK-3475) and its effects on the breast tumor microenvironment in triple-negative breast cancer; currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Eileen Connolly | Conditions: Triple Negative Breast Cancer | Phase 1 | Status: RECRUITING